# Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC

> **NCT02942706** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** mFOLFOX6
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT02942706
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11
- **Primary completion:** 2022-10
- **Final completion:** 2022-10
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2021-04-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02942706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02942706, "Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02942706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*